Literature DB >> 7971728

Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine.

R Pokorny, M J Finkel, W T Robinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7971728     DOI： 10.1023/a:1018965622014

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


× No keyword cloud information.
  1 in total

1.  Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry.

Authors:  B Saletu; J Grünberger; L Linzmayer; P Anderer
Journal:  Pharmacopsychiatry       Date:  1987-02       Impact factor: 5.788
  1 in total
  4 in total

Review 1.  Synergic development of pharmacokinetics and bioanalytical methods as support of pharmaceutical research.

Authors:  M Marzo; R Ciccarelli; P Di Iorio; P Giuliani; F Caciagli; A Marzo
Journal:  Int J Immunopathol Pharmacol       Date:  2015-12-18       Impact factor: 3.219

Review 2.  Generic clozapine: a cost-saving alternative to brand name clozapine?

Authors:  Gordon Tse; Deborah Thompson; Ric M Procyshyn
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

3.  Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type.

Authors:  Mohammad Hossain; Stanford S Jhee; Thomas Shiovitz; Craig McDonald; Greg Sedek; Francoise Pommier; Neal R Cutler
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers.

Authors:  Ahmed A Othman; George Haig; Hana Florian; Charles Locke; Lev Gertsik; Sandeep Dutta
Journal:  Br J Clin Pharmacol       Date:  2014-06       Impact factor: 4.335
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.